MK-6255 for advanced ovarian and endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called MK-6255 for people with ovarian or endometrial cancer that has come back or is hard to treat. It may be an option if standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that is platinum-resistant or has progressed after a PARP inhibitor, OR you have endometrial cancer that has progressed after at least one round of platinum-based chemotherapy.
- You have already tried all available standard treatments, unless you are not eligible for them or cannot tolerate them.
- You must provide a tumor tissue sample from a previous biopsy or have a new biopsy before starting treatment.
- If you have HIV, it must be well-controlled with antiretroviral therapy. If you have hepatitis B or C, the virus must be undetectable.
- Your organs (like kidneys, liver, heart) must be working well enough for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
This trial tests an investigational drug called MK-2750 for people with certain advanced cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.